Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Nov 02, 2022

BUY
$0.13 - $76.84 $380 - $224,987
2,928 New
2,928 $208,000
Q1 2021

May 11, 2021

SELL
$59.34 - $66.74 $191,549 - $215,436
-3,228 Closed
0 $0
Q4 2020

Feb 09, 2021

SELL
$57.74 - $65.43 $34,644 - $39,258
-600 Reduced 15.67%
3,228 $200,000
Q3 2020

Nov 12, 2020

SELL
$57.43 - $63.64 $223,230 - $247,368
-3,887 Reduced 50.38%
3,828 $231,000
Q2 2020

Aug 13, 2020

SELL
$54.82 - $64.09 $58,986 - $68,960
-1,076 Reduced 12.24%
7,715 $454,000
Q1 2020

May 11, 2020

BUY
$46.4 - $67.43 $11,878 - $17,262
256 Added 3.0%
8,791 $490,000
Q4 2019

Jan 30, 2020

SELL
$49.21 - $64.19 $8,119 - $10,591
-165 Reduced 1.9%
8,535 $548,000
Q3 2019

Nov 07, 2019

SELL
$42.77 - $50.71 $29,254 - $34,685
-684 Reduced 7.29%
8,700 $441,000
Q2 2019

Jul 25, 2019

SELL
$44.62 - $49.34 $37,927 - $41,939
-850 Reduced 8.31%
9,384 $426,000
Q1 2019

May 06, 2019

SELL
$45.12 - $53.8 $76,704 - $91,460
-1,700 Reduced 14.25%
10,234 $488,000
Q4 2018

Jan 22, 2019

SELL
$48.76 - $63.23 $207,230 - $268,727
-4,250 Reduced 26.26%
11,934 $620,000
Q3 2018

Nov 15, 2018

SELL
$55.19 - $62.25 $546,105 - $615,963
-9,895 Reduced 37.94%
16,184 $1.01 Million
Q2 2018

Aug 21, 2018

BUY
$50.53 - $62.98 $24,557 - $30,608
486 Added 1.9%
26,079 $1.44 Million
Q1 2018

May 14, 2018

SELL
$59.92 - $68.98 $542,216 - $624,200
-9,049 Reduced 26.12%
25,593 $1.62 Million
Q4 2017

May 14, 2018

BUY
$59.94 - $65.35 $2.08 Million - $2.26 Million
34,642
34,642 $2.12 Million

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $113B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Rice Partnership, LLC Portfolio

Follow Rice Partnership, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rice Partnership, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Rice Partnership, LLC with notifications on news.